|Status: One Wales interim decision|
Using the agreed starting and stopping criteria, vedolizumab (Entyvio®) can be made available within NHS Wales for the treatment of immune checkpoint inhibitor induced grade 3-4 enterocolitis, where symptoms have not responded to first line immunosuppression with corticosteroids and infliximab, or when infliximab is unsuitable.
The risks and benefits of the off-label use of vedolizumab (Entyvio®) for this indication should be clearly stated and discussed with the patient to allow informed consent.
Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.
This advice will be reviewed after 12 months or earlier if new evidence becomes available.
|Medicine name||vedolizumab (Entyvio®)|
|Formulation||powder for solution for infusion|
Treatment of immune checkpoint inhibitor induced grade 3-4 enterocolitis, where symptoms have not responded to first line immunosuppression with corticosteroids and/or other immunosuppressant drugs like infliximab, or when infliximab is unsuitable
|Company||Takeda UK Ltd|
|BNF chapter||Gastro-intestinal system|
|Submission type||One Wales|
|Status||One Wales interim decision|
|Date of issue||02/02/2023|